

# Ovarian cancer: identifying and managing familial and genetic risk

NICE guideline

Published: 21 March 2024

[www.nice.org.uk/guidance/ng241](https://www.nice.org.uk/guidance/ng241)

## Your responsibility

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian.

All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the [Yellow Card Scheme](#).

Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should [assess and reduce the environmental impact of implementing NICE recommendations](#) wherever possible.

# Contents

Overview .....	5
Who is it for? .....	5
Recommendations.....	6
1.1 Organisation of services.....	6
1.2 Information and support .....	10
1.3 Assessing the risk of having a pathogenic variant.....	18
1.4 Criteria for genetic counselling and genetic testing (in genetics services or in gynaecology oncology multidisciplinary services) .....	20
1.5 Gene panel testing .....	23
1.6 Assessing the risk of developing ovarian cancer .....	24
1.7 Primary preventive medicines .....	25
1.8 Risk-reducing surgery .....	26
1.9 Pathology protocol for handling specimens from risk-reducing surgery.....	32
1.10 Hormone replacement therapy after risk-reducing surgery .....	33
Terms used in this guideline.....	34
Recommendations for research .....	37
Key recommendations for research .....	37
Rationale and impact.....	40
Organisation of services.....	40
Information and support.....	43
Assessing the risk of having a pathogenic variant .....	48
Criteria for genetic testing .....	50
Gene panel testing .....	53
Assessing the risk of developing ovarian cancer.....	54
Primary preventive medicines.....	56
Risk-reducing surgery.....	57
Pathology protocol for handling specimens from risk-reducing surgery .....	63

Hormone replacement therapy after risk-reducing surgery .....	64
Context .....	66
Finding more information and committee details.....	67

## Overview

This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.

In women, trans men and non-binary people with female reproductive organs (ovaries, fallopian tubes and/or a uterus), having a pathogenic variant increases the risk of developing ovarian cancer (familial ovarian cancer). As well as risk assessment, this guideline covers risk management and decision-making support for people born with female reproductive organs who have, or are at risk of having, a pathogenic variant associated with ovarian cancer.

Men, trans women and non-binary people born with male reproductive organs cannot develop ovarian cancer, but if they have a pathogenic variant associated with ovarian cancer, they can pass the variant on to their children, and may be at risk of developing other cancers. This guideline covers risk assessment, but it does not cover managing risk or decision-making support for people born with male reproductive organs.

NICE has also produced a [guideline on the recognition and initial management of ovarian cancer](#).

## Who is it for?

- Healthcare professionals working in primary, secondary and tertiary care
- Cancer alliances
- Commissioners (including clinical commissioning groups and NHS England specialised commissioning)
- Voluntary sector organisations
- Adults (18 years and older) with a genetic risk of having a pathogenic variant associated with ovarian cancer, and their families and carers (where appropriate)

# Recommendations

People have the right to be involved in discussions and make informed decisions about their care, as described in [NICE's information on making decisions about your care](#).

[Making decisions using NICE guidelines](#) explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.

## 1.1 Organisation of services

### Commissioners and service providers in all settings (primary care, genetics services, gynaecology oncology and familial ovarian cancer multidisciplinary services)

- 1.1.1 Commissioners and service providers should ensure that there are referral pathways to genetics services and gynaecology oncology multidisciplinary services for people at risk of having a [pathogenic variant](#) associated with ovarian cancer. Such pathways can be facilitated by providing, for example:
- clear referral criteria (see [recommendation 1.3.1 in the section on assessing the risk of having a pathogenic variant](#))
  - an online referral form (to be completed by the referring clinician)
  - a family history questionnaire (to be completed by the person) that accompanies the referral form
  - information and support (see the [section on information and support](#)).
- 1.1.2 Commissioners and service providers should raise awareness of which groups of people may be at risk of having a pathogenic variant associated with ovarian

cancer.

1.1.3 Commissioners and service providers should ensure that there is training and information available for healthcare professionals on equality and inclusiveness issues that could improve access to services, for example, for people who:

- are from under-represented or underserved communities who may need more support to access services (for example, people who are physically disabled, people with neurodevelopmental conditions or a learning disability, people from Black, Asian and ethnic minority backgrounds, and people who are LGBTQ+)
- may not come forward for testing because they do not realise that they may be at risk of having a pathogenic variant associated with ovarian cancer (for example, men, trans women and non-binary people born with male reproductive organs).

## Primary care services

1.1.4 Primary care should be responsible for:

- providing information and support (see the [section on information and support](#))
- referral to genetics services and other specialist services (see recommendation 1.1.1 and [recommendation 1.3.1 in the section on assessing the risk of having a pathogenic variant](#)).

## Genetics services

1.1.5 Genetics services should be responsible for:

- providing information and support (see the [section on information and support](#))
- assessing the risk of having a pathogenic variant for people who do not have ovarian cancer

- genetic counselling and [genetic testing](#) for people who do not have ovarian cancer
- genetic counselling and genetic testing for people diagnosed with non-epithelial ovarian cancer (see [recommendation 1.4.6 in the section on people with ovarian cancer](#))
- arranging [cascade testing](#) of relatives, if appropriate
- assessing the risk of developing ovarian cancer
- discussing potential management options
- referral (if needed) to the familial ovarian cancer multidisciplinary team and other specialist services.

## Gynaecology oncology multidisciplinary team

- 1.1.6 The gynaecology oncology multidisciplinary team should be responsible for [mainstream genetic counselling and genetic testing](#) for people with invasive epithelial ovarian cancer.

## Familial ovarian cancer multidisciplinary team

- 1.1.7 The familial ovarian cancer multidisciplinary team should be responsible for:
- clinical care pathways and management protocols
  - the lifelong care of people at risk of familial ovarian cancer (those with a pathogenic variant or those above a risk threshold; see the [section on criteria for genetic counselling and genetic testing](#))
  - providing information and support (see the [section on information and support](#))
  - assessing the risk of developing ovarian cancer
  - discussing potential management options (for example, risk-reducing



surgery)

- carrying out surveillance and reviews
- liaising with other services and healthcare professionals, including primary care and specialist services (see recommendation 1.1.9)
- contributing to local and network audits
- facilitating access to clinical trials.

1.1.8 The familial ovarian cancer multidisciplinary team should have a designated lead clinician, and include healthcare professionals with expertise in areas including:

- clinical genetics
- gynaecology
- gynaecological oncology.

1.1.9 The familial ovarian cancer multidisciplinary team should have established relationships with, and agreed referral pathways to, other specialist services such as:

- psychological services
- menopause services
- fertility services
- breast cancer risk management services
- ovarian cancer services
- colorectal cancer services.

For a short explanation of why the committee made these recommendations and how they might affect services, see the [rationale and impact section on organisation of services](#).

Full details of the evidence and the committee's discussion are in [evidence review C: configuration of services](#).

## 1.2 Information and support

These recommendations are for anyone who has a familial or genetic risk of having a [pathogenic variant](#) associated with ovarian cancer. This includes women, men, trans people and non-binary people, and their family or carers (as appropriate).

### Information and support about familial ovarian cancer in all settings

- 1.2.1 Healthcare professionals in all settings (primary care, genetics services and specialist multidisciplinary services) should provide ongoing information and support in line with:
- table 1 on information and support about familial ovarian cancer in all settings
  - [NICE's guideline on patient experience in adult NHS services](#) – particularly the section on knowing the patient as an individual
  - [NICE's guideline on people's experience in adult social care services](#) – particularly the section on overarching principles related to enabling people to make decisions (for example, in relation to communication)
  - [NICE's guideline on shared decision making](#) – particularly the section on putting shared decision making into practice.

Table 1 Information and support about familial ovarian cancer in all settings

- Information about the risk of ovarian cancer from a person's family history.
- Information about the risk of ovarian cancer for people from Ashkenazi Jewish, Sephardi Jewish and Greenlander backgrounds.
- Information for men, trans women and non-binary people born with male reproductive organs who may have a genetic risk of having a [pathogenic variant](#) associated with ovarian cancer and other cancers.
- The message that if the person's family history alters (for example, if someone in their family develops ovarian cancer), their risk may alter.
- Advice to return to discuss any implications if there is a change in family history or symptoms develop.
- Ovarian cancer symptom awareness information – bloating, feeling full on eating, pelvic or abdominal pain, increased urinary urgency and/or frequency); also see the [section on awareness of symptoms and signs in the NICE guideline on ovarian cancer](#).
- Advice about ovarian cancer risk, including information about:
  - level of ovarian cancer risk in relation to the general population
  - hormone replacement therapy (HRT) and oral contraceptives
  - lifestyle factors
  - family size and timing.
- Information about referral for genetic counselling and [genetic testing](#).
- Information about the pathway for risk assessment and management.
- Information and support about referral to a different service, what the service does and why the person is being referred.
- Information and support about psychological factors such as anxiety, and psychological support services.
- Information about sources of support and information, for example, local and

national support groups and networks, patient organisations and specialist services.

- Reassurance about bringing a family member, friend or carer to appointments.

1.2.2 Healthcare professionals should ensure that information and support:

- supports shared decision making
- is balanced and accurate
- is available on an ongoing basis
- is available when needed
- is relevant to the person's circumstances
- is tailored to the person's needs, for example, it is in an accessible format or available in a different language.

1.2.3 Provide opportunities for people to review decisions, and share any additional information on how they can access services for further discussions, for example, at:

- re-referral to specialist services
- patient-initiated follow-up appointments directly with specialist services
- self-referral to genetics services.

1.2.4 At each appointment:

- ask the person about their emotional health
- ask about any psychological or emotional issues that could affect decision making, such as anxiety
- provide information and support (see [table 1 on information and support about familial ovarian cancer in all settings](#))

- discuss referral to genetic counselling or psychological services, as appropriate.
- 1.2.5 Raise awareness that men, trans women and non-binary people born with male reproductive organs can have a genetic risk of having a pathogenic variant associated with ovarian cancer and other cancers.
- 1.2.6 Ensure that services are easy to access (for example, by offering online appointments) and welcoming for everyone, particularly for people who may have additional support needs (also see [recommendation 1.1.3](#)).

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on information and support about familial ovarian cancer in all settings](#).

Full details of the evidence and the committee's discussion are in:

- [evidence review A: information and support](#)
- [evidence review B: support interventions](#)
- [evidence review D: optimal methods of assessing the probability of having a pathogenic variant](#)
- [evidence review F: carrier probability – any person](#)
- [evidence review H: populations with high prevalence](#).

## Information and support about risk assessment and genetic testing in genetics services

- 1.2.7 Healthcare professionals in genetics services should provide ongoing information and support in line with:
- table 2 on information and support about risk assessment and [genetic testing](#) in genetics services **and**

- [table 1 on information and support about familial ovarian cancer in all settings](#).

**Table 2 Information and support about risk assessment and genetic testing in genetics services**

### **At referral for risk assessment and genetic testing**

- Information about how the risk of having a [pathogenic variant](#) is assessed, and how to obtain a comprehensive family history (including up to [third-degree relatives](#)) if needed.
- Clarification about which family members could be at risk, and advice about appropriate ages for testing.
- Information about [genetic testing](#), including details of what genetic testing involves, what the tests mean and how informative they are likely to be, and the likely timescale of getting the results.
- Information and support on the importance of, and how to discuss, the results of assessment and testing with relatives, including different methods of contacting relatives about [cascade testing](#).
- Information about potential next steps depending on the risk assessment (including referral back to primary care, management within secondary care and/or a genetics service, risk-reducing surgery and surveillance).
- Information and support to aid decision making about topics such as genetic testing, risk-reducing surgery, fertility and whether the person wants to have children, and menopause and managing symptoms.
- Details of any trials or studies that may be appropriate.

### **If genetic testing has not been offered**

- Information about why genetic testing has not been offered (as applicable).
- Advice to return to primary care to discuss any implications if there is a change in family history or symptoms develop.

- 1.2.8 In genetics services, a healthcare professional with skills and experience in information provision and shared decision making specifically related to genetics and cancer risk should offer genetic counselling to people who meet the referral criteria for genetic testing. See the [sections on assessing the risk of having a pathogenic variant](#) and [criteria for genetic counselling and genetic testing](#).
- 1.2.9 Take into account the following factors when deciding whether to offer face-to-face or remote (for example, video call, telephone) genetic counselling:
- the person's preference
  - the decision that needs to be made (for example, genetic testing or risk-reducing surgery)
  - accessibility needs (for example, geographic location, digital access, language or communication impairment, participation of family members in other locations)
  - the need for an interpreter.
- 1.2.10 Consider giving information in a group session before an individual genetic counselling session.
- 1.2.11 Consider using a patient decision aid (for example, an app) alongside genetic counselling to support shared decision making. See the [recommendations on patient decision aids in the NICE guideline on shared decision making](#).

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on information and support about risk assessment and genetic testing in genetics services](#).

Full details of the evidence and the committee's discussion are in:

- [evidence review A: information and support](#)
- [evidence review B: support interventions](#)
- [evidence review D: optimal methods of assessing the probability of having a pathogenic variant](#)
- [evidence review F: carrier probability – any person](#).

## Information and support in specialist services if a person has a pathogenic variant or a strong family history of ovarian cancer

1.2.12 Healthcare professionals in specialist services (genetics services, gynaecology oncology multidisciplinary teams and familial ovarian cancer multidisciplinary teams) should provide ongoing information and support in line with:

- table 3 on information and support in specialist services if a person has a pathogenic variant or a [strong family history of ovarian cancer](#) **and**
- [table 1 on information and support about familial ovarian cancer in all settings](#).

**Table 3 Information and support in specialist services if a person has a pathogenic variant or a strong family history of ovarian cancer**



### **Risk of developing ovarian cancer**

- Information about the person's risk of developing familial ovarian cancer, how the risk is assessed, what their personal risk estimate means, and other factors that could increase or decrease the risk.
- Information and support to aid shared decision making.

### **Reproductive choices**

- Information about the likelihood of passing down the pathogenic variant to their children.
- Information about the impact of risk-reducing surgery on fertility.
- Information about the availability of fertility preservation by storing eggs or embryos.
- Information about the availability of pre-implantation genetic testing of embryos to avoid passing down the genetic risk to their children.

### **Risk-reducing surgery**

- Information about risk-reducing surgery and what it involves.
- Advice that risk-reducing bilateral salpingo-oophorectomy is the most reliable way to substantially reduce the likelihood of developing ovarian cancer and therefore improve life expectancy, but that there will still be a small residual risk.
- Information that, if risk-reducing bilateral salpingo-oophorectomy is appropriate, it is because of a pathogenic variant associated with ovarian cancer, or a family history that has been shown to increase risk.
- Information about the timing of risk-reducing surgery and different surgical procedures (also see the recommendations on risk-reducing mastectomy in the NICE guideline on familial breast cancer).
- The possible biopsychosocial and sexual consequences of risk-reducing surgery.
- Information about the possible impact of risk-reducing surgery on other areas of

the person's life, for example, that risk-reducing surgery will lead to early menopause (if premenopausal) and the symptoms they may experience, hormone replacement therapy (HRT), impact on sex life and body image, and fertility (see also the [section on people with cancer who wish to preserve fertility in the NICE guideline on fertility problems](#)).

- Information about ovarian cancer surveillance if they choose to delay or not have risk-reducing surgery – see [recommendation 1.8.6](#) for details of the information that should be given.
- Information about the risk of other cancers (for example, primary peritoneal, breast, pancreas, prostate or bowel cancer).

For a short explanation of why the committee made this recommendation and how it might affect practice, see the [rationale and impact section on information and support in specialist services if a person has a pathogenic variant or a strong family history of ovarian cancer](#).

Full details of the evidence and the committee's discussion are in:

- [evidence review E: optimal methods of assessing the absolute risk of having a pathogenic variant](#)
- [evidence review K: benefits and risks of surveillance](#)
- [evidence review N: risk-reducing surgery](#).

## 1.3 Assessing the risk of having a pathogenic variant

These recommendations are for anyone who has a risk of having a [pathogenic variant](#) associated with ovarian cancer. This includes women, men, trans people and non-binary people.

- 1.3.1 Healthcare professionals in primary care and secondary care should refer people for genetic counselling and genetic testing if any of the following apply:
- they have a first-degree relative with a diagnosis of ovarian cancer
  - they have a maternal or paternal second-degree relative with a diagnosis of ovarian cancer (this includes people with an unaffected intervening blood relative)
  - they meet the criteria for genetic testing as set out in the section on criteria for genetic counselling and genetic testing
  - they are from an at-risk population
  - they have been identified through cascade testing
  - they have a diagnosis of ovarian cancer as outlined in recommendation 1.4.6 and have not already had mainstream genetic testing.
- 1.3.2 If a person had a direct-to-consumer genetic test and is reported to have a pathogenic variant for which NHS testing is offered (for example, BRCA), healthcare professionals should liaise with the regional NHS genetics service to discuss whether referral is appropriate.
- 1.3.3 Genetics services should assess the probability of having a pathogenic variant using a calculation method with demonstrated accuracy, such as the Manchester scoring system, CanRisk (BOADICEA), BRCAPRO, or criteria based on specific clinical circumstances or a verified family history that are designed for the threshold used for testing.

For a short explanation of why the committee made these recommendations and how they might affect practice and services, see the [rationale and impact section on assessing the risk of having a pathogenic variant](#).

Full details of the evidence and the committee's discussion are in:

- [evidence review B: support interventions](#)
- [evidence review D: optimal methods of assessing the probability of having a pathogenic variant](#)
- [evidence review F: carrier probability – any person](#)
- [evidence review H: populations with high prevalence](#)
- [evidence review I: carrier probability – people with ovarian cancer](#).

## 1.4 Criteria for genetic counselling and genetic testing (in genetics services or in gynaecology oncology multidisciplinary services)

### Family history of ovarian cancer

These recommendations are for anyone who has a risk of having a [pathogenic variant](#) associated with ovarian cancer. This includes women, men, trans people and non-binary people.

1.4.1 Genetics services should offer genetic counselling and [genetic testing](#) to anyone who:

- has not had ovarian cancer **and**
- has a raised probability of having a pathogenic variant (see table 4 on genetic testing criteria) based on a verified family history **and**
- has a relative who has had a confirmed diagnosis of breast cancer or ovarian

cancer but genetic testing of the relative (or the tissue) is not possible or clinically appropriate (for example, consent is declined).

**Table 4 Criteria for carrying out genetic testing in genetics services**

<b>Age of the person</b>	<b>Women, trans men and non-binary people registered female at birth. Offer genetic counselling and genetic testing if the probability percentage of having a pathogenic variant is:</b>	<b>Men, trans women and non-binary people registered male at birth. Offer genetic counselling and genetic testing if the probability percentage of having a pathogenic variant is:</b>
30 to 39 years	2% or higher	6% or higher
40 to 49 years	2% or higher	9% or higher
50 to 59 years	3% or higher	10% or higher
60 to 69 years	6% or higher	10% or higher
70 years or over	10% or higher	10% or higher

- 1.4.2 If a person has not had ovarian cancer, genetics services should offer genetic counselling and genetic testing if they are a first-degree relative of a person with a known pathogenic variant (cascade testing).
- 1.4.3 If a person has not had ovarian cancer, genetics services should offer genetic counselling and genetic testing if:
- they are a second-degree or more distant blood relative of a person with a known pathogenic variant **and**
  - testing of an intervening blood relative is impossible or not clinically appropriate (for example, consent is declined).
- 1.4.4 If a person has a personal or family history of breast cancer, also see the NICE guideline on familial breast cancer, in particular the sections on the clinical significance of a family history of breast cancer, and referral to a specialist genetic clinic.

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on family history of ovarian cancer](#).

Full details of the evidence and the committee's discussion are in:

- [evidence review F: carrier probability – any person](#)
- [evidence review G: carrier probability – family history of a syndrome](#).

## At-risk populations

This recommendation is for anyone who has a risk of having a pathogenic variant associated with ovarian cancer. This includes women, men, trans people and non-binary people.

1.4.5 Recognise and raise awareness that people from the following populations (with at least 1 grandparent from the respective population), have a higher risk of having a [founder pathogenic variant](#) associated with familial ovarian cancer, so should be offered referral for genetic counselling and genetic testing for this variant, even if the person has no family or personal history of cancer:

- Ashkenazi Jewish
- Sephardi Jewish
- Greenlander.

Also see the [NHS Jewish BRCA Testing Programme](#), which offers BRCA testing to people with Jewish ancestry.

For a short explanation of why the committee made this recommendation and how it might affect practice, see the [rationale and impact section on at-risk populations](#).

Full details of the evidence and the committee's discussion are in [evidence review H: populations with high prevalence](#).

## People with ovarian cancer

This recommendation is for women, trans men and non-binary people born with any female reproductive organs (ovaries, fallopian tubes, uterus).

1.4.6 Offer pre-test counselling and [germline testing](#) to anyone diagnosed with:

- invasive epithelial ovarian cancer
- ovarian Sertoli–Leydig cell tumour
- small cell carcinoma of the ovary hypercalcaemic type
- ovarian sex cord tumour with annular tubules
- embryonal rhabdomyosarcoma of the ovary
- ovarian gynandroblastoma.

For a short explanation of why the committee made this recommendation and how it might affect practice and services, see the [rationale and impact section on people with ovarian cancer](#).

Full details of the evidence and the committee's discussion are in [evidence review I: carrier probability – people with ovarian cancer](#).

## 1.5 Gene panel testing

1.5.1 Select a gene panel from the [UK national genomic test directory](#) (see the [sections on assessing the risk of having a pathogenic variant and criteria for genetic counselling and genetic testing](#)) to test for [pathogenic variants](#).

1.5.2 Decide which gene panel from the [UK national genomic test directory](#) to use in relation to each person's family or personal history (for example, ovarian cancer alone, breast and ovarian cancer, or Lynch syndrome).

For a short explanation of why the committee made these recommendations and how they might affect practice and services, see the [rationale and impact section on gene panel testing](#).

Full details of the evidence and the committee's discussion are in [evidence review J: which genes to include in gene panel testing](#).

## 1.6 Assessing the risk of developing ovarian cancer

These recommendations are for women, trans men and non-binary people born with any female reproductive organs (ovaries, fallopian tubes, uterus).

- 1.6.1 If a person is under the care of genetics services or a familial ovarian cancer multidisciplinary team and has not had [genetic testing](#), the service or team should offer to assess their risk of developing ovarian cancer.
- 1.6.2 If a person has a [pathogenic variant](#) associated with an increased risk of ovarian cancer, the familial ovarian cancer multidisciplinary team should offer to assess their risk of developing ovarian cancer.
- 1.6.3 When assessing a person's risk of developing ovarian cancer:
- use a tool with demonstrated accuracy that includes their age, family history of ovarian and other cancers, and their pathogenic variant (such as CanRisk)
  - inform the person that there are other factors that could also increase or decrease their risk when using a tool or method that includes only limited information (for example, their age and pathogenic variant)
  - take into account factors that may not be accurately assessed by tools, for example, parity, use of the combined oral contraceptive pill, endometriosis, and whether relatives have only ovarian cancer.
- 1.6.4 When discussing a person's risk of developing ovarian cancer:
- provide a summary in the person's preferred format that includes their personal risk estimate **and**



- follow the recommendations in the [sections on communicating risks, benefits and consequences](#) and [putting shared decision making into practice in the NICE guideline on shared decision making](#).

1.6.5 For information on familial and other risk factors for breast cancer that also increase ovarian cancer risk, see the [NICE guideline on familial breast cancer](#).

For a short explanation of why the committee made these recommendations and how they might affect practice and services, see the [rationale and impact section on assessing the risk of developing ovarian cancer](#).

Full details of the evidence and the committee's discussion are in [evidence review E: optimal methods of assessing the absolute risk of having a pathogenic variant](#).

## 1.7 Primary preventive medicines

These recommendations are for women, trans men and non-binary people born with any female reproductive organs (ovaries, fallopian tubes, uterus), and who are at risk of epithelial ovarian cancer.

### Aspirin

- 1.7.1 Do not offer aspirin for the sole purpose of reducing ovarian cancer risk.
- 1.7.2 For recommendations on the use of aspirin for people with Lynch syndrome, see the [section on reduction in risk of colorectal cancer in people with Lynch syndrome in the NICE guideline on colorectal cancer](#).

### Combined oral contraceptives

- 1.7.3 Only consider the combined oral contraceptive pill to reduce the risk of ovarian cancer:
- if the reduction in the risk of developing ovarian cancer outweighs the

increased risk of developing breast cancer **and**

- after taking into account the timing of any risk-reducing surgery (mastectomy or salpingo-oophorectomy; see the [section on risk-reducing surgery](#)).

In March 2024, this was an off-label use of combined oral contraceptives. See [NICE's information on prescribing medicines](#).

- 1.7.4 Discuss the reduced risk of developing ovarian cancer and the increased risk of developing breast cancer when offering a combined oral contraceptive.

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on primary preventive medicines](#).

Full details of the evidence and the committee's discussion are in [evidence review M: preventive medicines](#).

## 1.8 Risk-reducing surgery

These recommendations are for women, trans men and non-binary people born with any female reproductive organs (ovaries, fallopian tubes, uterus), and who are at risk of epithelial ovarian cancer.

### Factors to take into account when considering risk-reducing surgery

- 1.8.1 Only offer risk-reducing surgery to people who have:

- completed their family or are not planning to conceive naturally (that is, they would only conceive using assisted reproduction) **and**
- a total lifetime risk of ovarian cancer of 5% or over because they have:
  - a [pathogenic variant](#) associated with familial ovarian cancer **or**

- a strong family history of ovarian cancer.

- 1.8.2 When discussing risk-reducing surgery, provide information and support in line with:
- table 3 on information and support in specialist services if a person has a pathogenic variant or a strong family history of ovarian cancer**and**
  - table 1 on information and support about familial ovarian cancer in all settings.
- 1.8.3 When discussing risk-reducing surgery, take into account psychological factors (such as anxiety) that could influence decision making. Discuss psychological support services available and, if needed, refer the person for psychological support before surgery.
- 1.8.4 When discussing risk-reducing bilateral salpingo-oophorectomy surgery with people who are premenopausal:
- offer specialist menopause counselling before and after surgery **and**
  - provide information and support to aid shared decision making (also see the section on information and support, in particular table 3 on information and support in specialist services if a person has a pathogenic variant or a strong family history of ovarian cancer, and the section on hormone replacement therapy after risk-reducing surgery).
- 1.8.5 Refer people who have bi-allelic pathogenic variants in mismatch repair genes (for example, homozygous PMS2), to a specialist tertiary team for discussions about risk-reducing surgery.

For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on factors to take into account when considering risk-reducing surgery.

Full details of the evidence and the committee's discussion are in evidence review N: risk-reducing surgery.

## Types of risk-reducing surgery and timing in relation to the person's specific pathogenic variant

The recommendations are for risk-reducing surgery related to ovarian cancer. For people who have a pathogenic variant that also increases their risk of breast cancer and are considering risk-reducing mastectomy, also see the [NICE guideline on familial breast cancer](#).

- 1.8.6 Offer risk-reducing surgery that is appropriate for the person's age, specific pathogenic variant and family history (including age of onset of any confirmed ovarian cancers in the family), after discussing the person's individual circumstances with the familial ovarian cancer multidisciplinary team. See table 5 on timing and types of risk-reducing surgery for people with a pathogenic variant that increases the risk of ovarian cancer.

**Table 5 Timing and types of risk-reducing surgery for people with a pathogenic variant that increases the risk of ovarian cancer**

Pathogenic variant	Procedure	Age (also see recommendation 1.8.11)
BRCA1	<a href="#">Bilateral salpingo-oophorectomy</a>	No earlier than 35 years
BRCA2	Bilateral salpingo-oophorectomy	No earlier than 40 years
RAD51C, RAD51D, BRIP1 or PALB2 <a href="#">pathogenic variant</a> with a total lifetime risk of ovarian cancer of 5% or over	Bilateral salpingo-oophorectomy	No earlier than 45 years
MLH1, MSH2 or MSH6	Hysterectomy with bilateral salpingo-oophorectomy (to reduce the risk of endometrial cancer as well as ovarian cancer)	No earlier than 35 years

- 1.8.7 Consider risk-reducing total hysterectomy alone to prevent endometrial cancer

for people (no earlier than 45 years) who have:

- a heterozygous PMS2 pathogenic variant **and**
- no family history of ovarian cancer.

- 1.8.8 If a person with a heterozygous PMS2 pathogenic variant has been offered total hysterectomy to prevent endometrial cancer, consider additional bilateral salpingo-oophorectomy depending on verified family history of ovarian cancer, age and menopausal status.
- 1.8.9 Consider risk-reducing surgery in people younger than the ages in table 5 on timing and types of risk-reducing surgery after carrying out an individualised risk assessment (including an assessment of menopausal symptoms) and providing information and support to aid shared decision making (also see the [section on information and support](#)).
- 1.8.10 Only offer risk-reducing bilateral salpingectomy with delayed oophorectomy as part of a clinical trial.
- 1.8.11 Do not carry out risk-reducing total hysterectomy in people with pathogenic variants other than MLH1, MSH2, MSH6 and PMS2, unless a personalised risk assessment shows a high risk of endometrial cancer that would necessitate hysterectomy or there is another gynaecological indication for hysterectomy.

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on types of risk-reducing surgery and timing in relation to the person's specific pathogenic variant](#).

Full details of the evidence and the committee's discussion are in [evidence review N: risk-reducing surgery](#).

## Tests before risk-reducing surgery

- 1.8.12 Before carrying out risk-reducing bilateral salpingo-oophorectomy, perform a transvaginal ultrasound and a serum CA125 test to minimise the risk of missing

asymptomatic ovarian cancer.

- 1.8.13 Before carrying out a risk-reducing hysterectomy, perform an endometrial biopsy to minimise the risk of missing asymptomatic endometrial cancer.

## Referral to the gynaecology oncology multidisciplinary team

- 1.8.14 If asymptomatic cancer is identified by preoperative investigation or postoperative histopathological or cytopathological analysis, refer the person to the gynaecology oncology multidisciplinary team (see the [section on the gynaecology oncology multidisciplinary team](#)).

## During risk-reducing surgery

- 1.8.15 Carry out risk-reducing minimal access surgery, unless a laparotomy is more clinically appropriate.
- 1.8.16 Take peritoneal washings during risk-reducing surgery for cytological examination to test for the presence of malignant cells.
- 1.8.17 If any suspicious lesions are found outside the organs being removed, take a biopsy if it is feasible and safe to do.

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on tests before risk-reducing surgery, referral to the gynaecology oncology multidisciplinary team, and what to consider during surgery](#).

Full details of the evidence and the committee's discussion are in [evidence review N: risk-reducing surgery](#).

## Ovarian cancer surveillance by the familial ovarian cancer multidisciplinary team for people who choose to delay or not have risk-reducing surgery

These recommendations are for women, trans men, non-binary people born with any female reproductive organs (ovaries, fallopian tubes, uterus).

- 1.8.18 If a person is at risk of developing ovarian cancer and chooses to delay or not have risk-reducing surgery, discuss their reasons and explain that:
- they have an increased risk of developing ovarian cancer and that the only way to reduce their risk is to have risk-reducing surgery
  - delaying risk-reducing surgery should only be seen as a short-term option
  - regular surveillance does not reduce their risk of developing ovarian cancer
  - although regular surveillance means that ovarian cancer may be detected earlier, they should not view surveillance as an alternative to risk-reducing surgery (because there is little evidence on whether this leads to improved outcomes and saves lives)
  - surveillance will involve them having a blood test every 4 months to check their level of the protein CA125 (cancer antigen 125), with an algorithm to analyse results, and a review at least once a year to discuss the recommendation of having risk-reducing surgery
  - there is a possibility of getting a false-positive or false-negative test result.
- 1.8.19 The familial ovarian cancer multidisciplinary team (see the [section on familial ovarian cancer multidisciplinary teams](#)) should only consider surveillance for people in the following groups who are at risk of developing ovarian cancer but who choose to delay or not have risk-reducing surgery (see also [table 5 on timing and types of risk-reducing surgery](#)):
- over 35 and have a BRCA1 pathogenic variant **or**
  - over 40 and have a BRCA2 pathogenic variant **or**
  - over 45 and have RAD51C, RAD51D, BRIP1 and PALB2 pathogenic variants.

- 1.8.20 If carrying out surveillance (see recommendation 1.8.19), the familial ovarian cancer multidisciplinary team should:
- carry out serial 4-monthly CA125 longitudinal testing using an algorithm with demonstrated accuracy (for example, the Risk of Ovarian Cancer Algorithm [ROCA] Test)
  - coordinate, audit and interpret CA125 testing using a call and recall system
  - have a review appointment with the person at least once a year to discuss the recommendation of having risk-reducing surgery (see the [section on risk-reducing surgery](#)).

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on ovarian cancer surveillance in secondary care for people who choose to delay or not have risk-reducing surgery](#).

Full details of the evidence and the committee's discussion are in:

- [evidence review K: benefits and risks of surveillance](#)
- [evidence review L: methods of surveillance](#).

## 1.9 Pathology protocol for handling specimens from risk-reducing surgery

- 1.9.1 Submit all ovaries and fallopian tubes for histological examination using a SEE-FIM (Sectioning and Extensively Examining the FIMbriated End) protocol.
- 1.9.2 Carry out immunohistochemistry (p53 and Ki67/MIB1) only if a premalignant or malignant lesion is suspected on morphological examination.
- 1.9.3 Submit the adnexa in separate, appropriately labelled specimen containers so that the laterality is available to the pathologist. Include this information in the pathology report.



- 1.9.4 Always perform peritoneal cytology when carrying out risk-reducing surgery.
- 1.9.5 Submit the entire endometrium, including the lower uterine segment, for histological examination in risk-reducing hysterectomy specimens in people with Lynch syndrome.

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on pathology protocol for handling specimens from risk-reducing surgery](#).

Full details of the evidence and the committee's discussion are in [evidence review O: pathology protocol](#).

## 1.10 Hormone replacement therapy after risk-reducing surgery

These recommendations are for women, trans men and non-binary people who have had risk-reducing surgery on female reproductive organs.

- 1.10.1 Offer hormone replacement therapy (HRT) until the average age of menopause (usually around 51 years) for people who:
- have not had breast cancer **and**
  - have had risk-reducing [bilateral salpingo-oophorectomy](#) before the average age of menopause.
- 1.10.2 Liaise with the person's breast cancer care team before offering HRT to people who:
- have had breast cancer **and**
  - have had risk-reducing bilateral salpingo-oophorectomy.
- 1.10.3 When offering HRT to people who meet the criteria in recommendation 1.10.1:
- use combined HRT for people who have a uterus

- use oestrogen-only HRT for people who do not have a uterus
- start HRT as soon as clinically appropriate after surgery
- consider the insertion of a levonorgestrel intrauterine system at time of surgery
- discuss the individual risks and benefits of HRT use beyond the average age of menopause.

1.10.4 Offer vaginal oestrogen to people with genitourinary symptoms associated with menopause, who have not had breast cancer.

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on HRT after risk-reducing surgery](#).

Full details of the evidence and the committee's discussion are in [evidence review P: HRT after risk-reducing surgery](#).

## Terms used in this guideline

This section defines terms that have been used in a particular way for this guideline. For other definitions, see the [NICE glossary](#) and the [Think Local, Act Personal Care and Support Jargon Buster](#).

### Bi-allelic

Of or relating to both alleles of a single gene (paternal and maternal).

### Bilateral salpingo-oophorectomy

A surgical procedure to remove both (bilateral) fallopian tubes (salpingectomy) and the ovaries (oophorectomy).

## **Cascade testing**

A systematic process to identify individuals within a family at risk of developing a hereditary condition. Cascade testing begins with finding a pathogenic variant through testing (such as multigene panel testing) in 1 family member, usually affected by the condition. Then, testing just for the specific family variant is extended to blood relatives. This process is repeated as more affected individuals or pathogenic variant carriers are identified.

## **First-degree relative**

Mother, father, daughter, son, sister or brother.

## **Founder pathogenic variant**

A genetic alteration observed with high frequency in a group that is or was geographically or culturally isolated, in which 1 or more of the ancestors was a carrier of the altered gene.

## **Genetic testing**

The study of a person's DNA in order to identify potentially disease-causing differences (pathogenic variants) or susceptibility to particular diseases or abnormalities.

## **Germline testing**

A type of genetic test that looks for inherited mutations that are present in the DNA of every cell of the body and have been present since birth.

## **Intervening blood relative**

A relative on the same side of the family who is more closely related to the family member with ovarian cancer than the person themselves.

## **Mainstream pre-test counselling and genetic testing**

Pre-test counselling, consent and genetic testing being undertaken at the point of care by a member of the gynaecology oncology multidisciplinary team rather than genetics

services.

## **Mismatch repair genes**

Mismatch repair (MMR) genes code for proteins that are involved in correcting mistakes made when DNA is copied in a cell. MMR-deficient cells usually have many DNA alterations, which may lead to cancer.

## **Pathogenic variant**

A genetic alteration that increases a person's susceptibility or predisposition to a certain disease or disorder. If someone has a pathogenic variant, they are sometimes known as a 'carrier'. This is because they 'carry', and can pass on to their children, a pathogenic variant associated with a disease (or trait) that is inherited in an autosomal dominant, autosomal recessive manner, even though they do not show symptoms of that disease (or features of that trait). The likelihood of having the pathogenic variant is also known as their 'carrier probability'.

In this guideline, the term 'pathogenic variant' refers to the presence of a pathogenic variant or 'likely pathogenic variant' (which is a variant with strong evidence that suggests it is associated with an increased risk of ovarian cancer).

## **Second-degree relative**

Grandparent, grandchild, aunt, uncle, niece, nephew, half-sister or half-brother.

## **Strong family history of ovarian cancer**

A person has a strong family history of ovarian cancer if they have 1 or more first-degree relatives (for example, a grandmother, mother, sister or daughter) on the same side of their family (the mother's or father's side of the family) with ovarian cancer.

## **Third-degree relative**

Great grandparent, great grandchild, great aunt, great uncle, first cousin, grandnephew or grandniece.

# Recommendations for research

The guideline committee has made the following recommendations for research.

## Key recommendations for research

### 1 Interventions to support decision making

What is the effectiveness of psychological interventions to support decision making by people who meet the referral criteria for genetic testing?

For a short explanation of why the committee made this recommendation for research, see the [rationale section on information and support about risk assessment and genetic testing in genetics services](#).

Full details of the evidence and the committee's discussion are in [evidence review B: support interventions](#).

### 2 Assessing a person's risk of having a pathogenic variant associated with familial ovarian cancer

What are the optimal tools to assess mutation carrier probability for a wider range of ovarian cancer susceptibility genes, not limited to BRCA1 and BRCA2?

For a short explanation of why the committee made this recommendation for research, see the [rationale section on assessing the risk of having a pathogenic variant](#).

Full details of the evidence and the committee's discussion are in [evidence review D: optimal methods of assessing the probability of having a pathogenic variant](#).

### 3 Assessing the risk of developing ovarian cancer

What are the performance characteristics of tools or models to assess the absolute risk of developing ovarian cancer?

For a short explanation of why the committee made this recommendation for research, see the [rationale section on assessing the risk of developing ovarian cancer](#).

Full details of the evidence and the committee's discussion are in [evidence review E: optimal methods of assessing the absolute risk of having a pathogenic variant](#).

### 4 Ovarian cancer surveillance

What are the long-term benefits and risks of ovarian cancer surveillance for people at increased risk of ovarian cancer?

For a short explanation of why the committee made this recommendation for research, see the [rationale section on ovarian cancer surveillance by the familial ovarian cancer multidisciplinary team for people who choose to delay or not have risk-reducing surgery](#).

Full details of the evidence and the committee's discussion are in [evidence review K: benefits and risks of surveillance](#).

### 5 Hormone replacement therapy after risk-reducing surgery

What is the safety and efficacy of hormone replacement therapy (HRT) after risk-reducing salpingo-oophorectomy?

For a short explanation of why the committee made this recommendation for research, see the [rationale section on HRT after risk-reducing surgery](#).

Full details of the evidence and the committee's discussion are in [evidence review P: HRT after risk-reducing surgery](#).

## 6 Primary preventive medicines

What is the effectiveness of primary preventive medicines for reducing the incidence of ovarian cancer in people at increased risk of familial ovarian cancer?

For a short explanation of why the committee made this recommendation for research, see the [rationale section on primary preventive medicines](#).

Full details of the evidence and the committee's discussion are in [evidence review M: preventive medicines](#).

# Rationale and impact

These sections briefly explain why the committee made the recommendations and how they might affect practice or services.

## Organisation of services

Recommendations 1.1.1 to 1.1.9

### Why the committee made the recommendations

There was limited evidence, with a small number of studies and uncertainties about the effect size and the way the studies were conducted, so the committee based the recommendations on the evidence and their knowledge and experience.

### **Commissioners and service providers in all settings (primary care, genetics services, gynaecology oncology and familial ovarian cancer multidisciplinary services)**

The committee discussed their experience of variations in how people are referred from healthcare professionals, for example, whether people are referred first to specialist gynaecological services or directly to genetic specialist services. They decided to recommend direct referral to make services more efficient, together with ways of making the referral process smoother (including clearer referral criteria).

The committee discussed their experience of why people who may be at risk of having a pathogenic variant associated with ovarian cancer do not access services. They agreed that people from under-represented or underserved groups may know that the guideline applies to them but may need more support to access services. This could include people who are physically disabled, people with neurodevelopmental conditions or a learning disability, people from Black, Asian and ethnic minority backgrounds, and people who are LGBTQ+. In addition, people may not realise that they may be at risk of having a pathogenic variant associated with ovarian cancer because they cannot develop ovarian cancer, for example, men, trans women and non-binary people born with male reproductive organs. The committee agreed that these groups need encouragement to discuss referral to genetics services. The committee further noted that healthcare



professionals are not always aware of the potential barriers, and agreed that training and information would help raise awareness.

The committee also noted that there is an overall lack of awareness, which is a barrier to identification of people at risk. They decided, based on their experience, that it should be within the remit of commissioners and service providers to raise awareness both among healthcare professionals and the general public. A lack of knowledge about who may be eligible (for example, people from at-risk populations) could lead to a delay in assessment and identification of people at risk, and this has potentially serious consequences, such as the risk of developing ovarian cancer. Including this information in continuing education programmes and having public awareness initiatives could be ways to help raise awareness.

### **Primary care services**

The committee discussed that primary care has limited capacity to seek out potential index cases. However, if a family history is known (including family history from a population with increased risk), a person is known to be from an at-risk population or a person has ovarian cancer, GPs can refer people directly to genetics services. The committee also noted that information and support should be provided in primary care to enable people to make informed decisions.

### **Genetics services**

In the committee's experience, there is little variation in the responsibilities of genetics services because their services are specified by [NHS England commissioning guidance](#) for medical genetics services. The committee agreed to list the main responsibilities so that people know what to expect when they are being referred.

The committee discussed whether rarer types of ovarian cancer would be the responsibility of genetics services or gynaecology oncology services. It was agreed that the care of these types of genetic conditions (see the non-epithelial ovarian cancers listed in recommendation 1.4.6) is very specialised and that therefore genetic counselling and genetic testing should be within the remit of genetics services.

### **Gynaecology oncology multidisciplinary team**

Based on the evidence about mainstream genetic testing and counselling, which showed

services run more efficiently and faster, the committee agreed that mainstream genetic counselling and genetic testing of anyone with a histopathological diagnosis of epithelial ovarian cancer should be carried out by their gynaecology oncology multidisciplinary team.

### **Familial ovarian cancer multidisciplinary team**

Having a pathogenic variant or being above a threshold for testing leads to many decisions having to be made during the person's life, for example, in relation to fertility and risk-reducing surgery. The committee acknowledged that services run more effectively when roles and responsibilities are defined so that staff and people using the services know what to expect. They noted that the person's care would need to be coordinated because different services may become relevant to them at different points in their life (including, for example, providing information and support, and carrying out reviews). The committee decided that a multidisciplinary approach would be beneficial and that this should continue throughout the person's life. They clarified that the person would usually see the appropriate person relevant to their circumstances and would not usually see the entire team.

Based on their experience, the committee specified the expertise that is essential for the familial ovarian cancer multidisciplinary team (core expertise that is always required) and the other services that the multidisciplinary team would need access to, such as menopause services.

### **How the recommendations might affect services**

The committee discussed that some of these services already exist but that there is variation in practice in how referral between them takes place and how they are set up.

The committee noted that broader eligibility criteria for genetic testing may result in more pressure on existing services, such as primary care. However, people are generally responsible for the completion of their family history questionnaires and specialist service referrals can be completed quickly online, which may help to mitigate some of the pressure on primary care services.

Not all trusts have dedicated familial ovarian cancer multidisciplinary teams, and there is variation in practice. The committee noted that similar teams already exist for breast cancer, and have improved outcomes. Although the recommendations may incur initial

set-up costs, these will be offset by improved outcomes. The recommendations will also standardise service organisation. The committee also noted that, although access to specialists is essential and the overall care is coordinated by them, specialists do not need to be located in a single clinic, potentially mitigating the resource impact on services.

[Return to recommendations](#)

## Information and support

### Information and support about familial ovarian cancer in all settings

[Recommendations 1.2.1 to 1.2.6 and table 1](#)

#### Why the committee made the recommendations

The committee based their recommendations on qualitative evidence.

There was evidence that although people want information tailored to their individual situation, preferences and needs, this does not always happen. In addition, people want information at the most appropriate time, as well as several opportunities for discussions. There was also evidence that information about risks can be difficult to digest for people and varies according to each person's circumstances. There was evidence highlighting that people can feel overwhelmed by the volume and complexity of information and feel that it is not always sufficiently individualised. There was also evidence about the importance of involving families. The committee agreed the importance of providing sufficient information on an ongoing basis, tailored to the person's needs, so that people can make informed choices.

The evidence showed that rather than receiving all information at once, which can be overwhelming, people appreciate having opportunities to review their decisions at key stages in the pathway. The committee noted that people would need to know how they can access services to make these discussions possible, and recommended providing opportunities to address this.

There was evidence that the considerable psychological impact is not always sufficiently addressed, so the committee recommended that healthcare professionals ask people

about their emotional health and wellbeing at each appointment. This means that onward referral to genetic counselling or psychological services can be arranged if needed, for example, in situations where there is anxiety around testing or severe emotional distress.

There was evidence that many people believe that genetic risk only affects women and people born with female reproductive organs. The committee agreed that this perpetuates a lack of clarity around the risk for men, trans women and non-binary people born with male reproductive organs, and discussed the need to raise awareness about the risks.

Based on their knowledge and experience, and the equality impact assessment for this guideline, the committee highlighted that some groups may need additional support to access services, for example, by having online rather than in-person appointments.

To emphasise the need for standard information in all settings and the content of this information, the committee highlighted key information that should be given to people.

## **How the recommendations might affect practice**

The committee agreed that it is current practice to provide information and support but noted that there is variation in when, what and how often it is provided. The recommendations should lead to greater consistency. Although this may take up additional time, it will allow people to better understand their risk and make informed choices. For example, appropriate information and support at the right time may mean a person choosing to have risk-reducing surgery, which will substantially reduce their cancer risk and associated healthcare costs. Also, existing processes to provide similar information and support to those at risk of familial breast cancer should help lessen the resource impact.

[Return to recommendations](#)

## **Information and support about risk assessment and genetic testing in genetics services**

[Recommendations 1.2.7 to 1.2.11 and table 2](#)

### **Why the committee made the recommendations**

The committee based the recommendations on the evidence and their knowledge and

experience. They discussed that informed choices can only be made if good information is provided, and agreed that information and support is needed when people come to genetics services, so summarised the information that should be provided as a minimum.

Evidence showed that, compared with usual care, genetic counselling is associated with a higher uptake of the options being considered and higher scores on a knowledge questionnaire about ovarian cancer risk (it could be inferred that better knowledge would lead to a higher-quality decision). The committee acknowledged that genetic counselling would not be needed by everyone but recommended it for people who meet the referral criteria for genetic testing.

Evidence comparing telephone with face-to-face genetic counselling showed no differences in outcomes apart from a higher uptake of options with face-to-face counselling. Economic evidence also showed telephone counselling to be a cost-effective option. The committee noted that the evidence was from 2014 and that online genetic counselling has become a lot more common since the COVID-19 pandemic. They agreed that online or face-to-face counselling should be offered. They also noted that certain factors may influence which option is most preferable. For example, face-to-face counselling may be more appropriate if an interpreter is needed, whereas online counselling may be more appropriate if family members in a different geographical location are attending the session.

The committee considered clinical and economic evidence that compared a group session in which a video was shown before individual genetic counselling sessions, with individual sessions alone. The committee noted that there were not many clinical differences but that there were cost savings associated with group sessions. The committee agreed that a group session before the individual session could be an option. Despite the potential cost savings, the committee did not want to be prescriptive about this because circumstances can vary widely (for example, level of risk, level of distress or other factors such as communication or language difficulties), which may mean that an individual session may be preferable for some people.

Using a decision aid alongside genetic counselling showed benefits compared with genetic counselling alone for some outcomes such as higher satisfaction with the support received and better decision quality. Adding a decision aid was also associated with a higher number of people taking up the option that was considered (which related to ovarian cancer screening). However, the evidence was not clear about the components used in the decision aid so the committee's recommendation reflected the uncertainty

about whether a decision aid made up of different components would be equivalently effective. The committee noted general principles related to decision aids in the NICE guideline on shared decision making.

To emphasise the need for standard information about risk assessment and genetic testing in genetics services and the content of this information, the committee highlighted key information that should be given to people.

There was no evidence for any particular type of psychological intervention to support decision making so the committee therefore made a recommendation for research on the effectiveness of psychological interventions. However, the committee noted that making decisions related to cancer risk can be stressful and can cause some people considerable distress because it may impact their families' lives as well as their own, so psychological support could be beneficial.

### **How the recommendations might affect practice**

Genetic counselling is current practice. However, the broader eligibility criteria for genetic testing may lead to an increased demand for these services, resulting in additional pressure on existing genetics services. Some of this pressure may be reduced by people choosing remote counselling or having group counselling sessions before individual genetic counselling.

The provision of group counselling varies in practice and there may be some implementation costs for services that do not already provide this. However, providing group counselling would result in shorter individual counselling sessions, thereby helping to alleviate some of the pressure on genetics services and potentially leading to cost savings over time. Remote counselling may be more efficient and it may, for example, enable more appointments to take place.

Patient decision aids (or aids that help the healthcare professional make decisions) are already used in some services but there is variation in practice. The recommendation would make decision aids more available in practice. Healthcare professionals already provide a range of approaches to support decision making so adapting this to the relevant decision context would not change current practice.

It is already current practice to refer someone who is distressed or has difficulties in reaching a decision, for psychological support. The recommendation may potentially

increase referrals, but addressing such problems early on could result in significant benefits to patients and cost savings to the NHS. For example, a lack of psychological support may prevent engagement with care, or delay genetic testing or risk-reducing surgery uptake.

The committee highlighted the limited availability of specialised psychological services in some regions, specifically those designed to deal with psychological issues arising due to genetic testing and risk management. They noted that all services should have referral pathways to psychological services so that people in psychological distress can receive the support they need. The committee also recognised that genetic counselling could help address certain psychological concerns and that some people may need only 1 consultation with a psychologist, thus mitigating the potential impact on psychological services.

[Return to recommendations](#)

## **Information and support in specialist services if a person has a pathogenic variant or a strong family history of ovarian cancer**

[Recommendation 1.2.12 and table 3](#)

### **Why the committee made the recommendation**

The committee based the recommendation on qualitative evidence and evidence about other specialist assessment or risk management services or strategies.

The evidence showed that people want information at the most appropriate time, as well as several opportunities for discussions. An important time for this would be when the person knows that they have a pathogenic variant or a strong family history of ovarian cancer. The committee agreed the importance of providing sufficient information on an ongoing basis. They recommended that in specialist services, people should receive general as well as more specific information depending on their circumstances. There was evidence that women are concerned about reproductive options and how having a pathogenic variant affects this. The committee therefore also agreed that people should have information about reproductive choices and risk-reduction options.

To emphasise the need for standard information in specialist services if a person has a pathogenic variant and the content of this information, the committee highlighted key

information that should be given to people.

## How the recommendation might affect practice

The committee agreed that it is current practice to provide information and support, but noted that there is variation in when, what and how often it is provided. The recommendation should lead to greater consistency. Although this may take up additional time, it will allow people to better understand their risk and make informed choices. This will improve people's satisfaction with services and may reduce their risk of developing ovarian cancer and associated healthcare costs.

[Return to recommendation](#)

# Assessing the risk of having a pathogenic variant

[Recommendations 1.3.1 to 1.3.3](#)

## Why the committee made the recommendations

The committee based the recommendations on evidence as well as their knowledge and experience. The available evidence only focused on tools that identify people at risk of carrying a BRCA1 or BRCA2 pathogenic variant.

The committee agreed that healthcare professionals need a set of simple criteria to know when a person should be referred for genetic counselling and genetic testing. They agreed that all people should be referred to genetics services who meet the criteria for genetic testing to identify people at risk of having a pathogenic variant. They emphasised that this would not only include people coming forward for testing but also family members of people with a pathogenic variant who would be referred for cascade testing. People who are unaffected by ovarian cancer but have a first- or second-degree relative with a diagnosis of ovarian cancer may also have concerns about having a genetic risk, so can also be referred. The committee clarified that this would apply to any first-degree relative of someone with ovarian cancer. They clarified that for people with second-degree relatives with ovarian cancer, this applies to the maternal and paternal sides, even if the intervening relative is not affected (which would be in line with the thresholds in table 4). Other criteria relate to people from at-risk populations and those with a diagnosis of ovarian cancer (who may already be under the care of gynaecology oncology services responsible for genetic counselling and genetic testing).



The committee noted that genetic tests are now commercially available (known as direct-to-consumer testing), and discussed what would happen if a person accesses NHS services and presents with a positive genetic test result. They agreed that not all direct-to-consumer laboratories produce accurate test results or prepare people for their test results. Therefore, positive test results for a pathogenic variant for which NHS testing is offered will need to be discussed with an NHS genetics service to decide if referral is needed. This is consistent with the [joint guidance by the Royal College of GPs and the British Society for Genetic Medicine](#).

There was evidence that there are a number of tools with good performance statistics (sensitivity, specificity and area under the curve) to identify BRCA1 and BRCA2 variants. The committee provided examples of tools (those with the largest evidence base) but did not want to be too prescriptive because other tools had good accuracy (with less evidence) and further calculation methods could be developed. The committee noted that some clinical circumstances and the particular family history would impact the tool that is used. They also discussed that sometimes people describe family histories which they believe to be ovarian cancer even if it was another type of gynaecological cancer, and this contributes to potentially inappropriate referral for genetic testing. They therefore recommended that family histories should be verified (for example, via the Cancer Registry or other medical documents).

Given the uncertainties about variants other than BRCA1 and BRCA2 and to address the gap in the evidence, the committee also made a [recommendation for research on optimal tools to assess mutation carrier probability for a wider range of ovarian cancer susceptibility genes, not limited to BRCA1 and BRCA2](#).

## How the recommendations might affect practice and services

The committee noted that once criteria are met, it is current practice to arrange a referral to genetics services. The criteria have changed (see the rationale and impact sections for section 1.4) and therefore some of the referral criteria have changed in line with these. The committee noted that referring people for genetic counselling and genetic testing if they have a first-degree relative with ovarian cancer is current practice. However, referring people with a second-degree relative who has ovarian cancer if they do not have an affected intervening relative is not current practice (particularly on the maternal side), but is in line with the thresholds in table 4. This change would be associated with a resource impact, however, this will lead to more people being identified and taking up risk management.

Direct-to-consumer testing is becoming more popular. The recommendation will standardise practice and possibly reduce the burden on services having to manage unreliable test results. The committee agreed that there are significant NHS costs in confirming or refuting direct-to-consumer testing results and these are not warranted unless there are clinical indications for testing. By liaising with NHS genetics services, it can be ensured that only people at increased risk are referred. This is consistent with the joint guidance by the Royal College of GPs and the British Society for Genetic Medicine and should be current practice for most services.

Some tools are already being used but there is variation in practice. Where they are currently not used, introducing them will not incur a substantial cost and will lead to better identification and risk management.

[Return to recommendations](#)

## Criteria for genetic testing

### Family history of ovarian cancer

[Recommendations 1.4.1 to 1.4.4 and table 4](#)

#### Why the committee made the recommendations

The committee based the thresholds for genetic testing on results from an economic model that had been specifically conducted, which showed variation in the cost effectiveness of panel genetic testing, where the thresholds differed according to gender and age.

The committee discussed that cascade testing of family members of people with a pathogenic variant is already current practice. This helps to identify people who also have the same pathogenic variant so that risks can be managed to help prevent cancer. The committee also noted that it is important to make recommendations for people in situations where it is impossible or not clinically appropriate to test the relative who has ovarian or breast cancer (or the tissue), or where people have a distant relative with a known pathogenic variant but a closer relative cannot be tested.

The committee discussed genetic testing for people with a personal or family history

suggestive of a clinically defined syndrome associated with an increased risk of ovarian cancer. They did not make any recommendations because people would be tested or cascade tested if they or a family member had any of the syndromes specified in the protocol. They also decided not to make a research recommendation for this topic because these syndromes are very rare, so research would be unlikely or unfeasible.

## **How the recommendations might affect practice**

Testing when a person has less than a 10% of having a pathogenic variant is not current practice and the recommendations will make testing available to more people. This may require service providers to make healthcare professionals and the public aware of this change, and to make arrangements for implementation. This could also increase the demand for support services such as psychological and menopause services. However, this will lead to more people being identified and taking up risk management, and is a cost-effective approach. Recommendations related to cascade testing are current practice.

[Return to recommendations](#)

## **At-risk populations**

[Recommendation 1.4.5](#)

### **Why the committee made the recommendation**

The committee considered clinical as well as economic evidence. The clinical evidence summarised the prevalence of pathogenic variants associated with ovarian cancer.

The evidence showed that the prevalence of BRCA1 and BRCA2 is higher in people from Ashkenazi Jewish families (between 1.2% and 2.2%). The evidence also showed a higher prevalence of BRCA1 in Greenlander people (between 1.1% and 11.64%).

Although the prevalence is lower in people from Sephardi Jewish populations compared with Ashkenazi Jewish populations, there was economic evidence that testing of Ashkenazi and Sephardi Jewish people is cost effective even if only 1 grandparent is from the population. Based on this evidence, the committee used 'at least 1 grandparent' as the definition for being from the specified population.

The committee agreed that the economic evidence supports genetic counselling and genetic testing for people from the at-risk populations specified, even if the family background is the only criterion for genetic testing. However, they noted that this would not be done through a centrally coordinated national screening programme, but that awareness should be raised about the higher risk of having a founder pathogenic variant so that people could come forward for testing. Healthcare professionals should then recognise that the risk in these populations is higher and offer people referral to genetics services.

### **How the recommendation might affect practice**

The committee discussed that more people from at-risk populations may come forward for genetic counselling and genetic testing, which will have resource implications. However, they noted that this would not be full panel testing but only testing for the founder genetic variant, which would be less costly.

The committee noted that the recommendation may initially be difficult to implement if more people access genetics services, which are already overstretched. The committee agreed that the impact will reduce after the first wave because numbers would become naturally smaller. However, the recommendation could also increase the demand on existing support services, including psychological and menopause services. Raising awareness and increasing access to genetic counselling and genetic testing among at-risk populations will, however, identify more people who will participate in risk management, which is a cost-effective approach.

The committee noted that there is an NHS programme offering BRCA testing to those with Jewish ancestry (the [NHS Jewish BRCA testing programme](#)) as well as a published programme model ([A collaborative genetic carrier screening model for the British Ashkenazi Jewish community](#)), and agreed that linking up with these projects may make implementation easier because some of the pathways into the services would already be established.

[Return to recommendation](#)

## **People with ovarian cancer**

### Recommendation 1.4.6

## Why the committee made the recommendation

The committee discussed the evidence that in people with ovarian cancer, the overall prevalence of BRCA1 and BRCA2 pathogenic variants is around 17%. When grouped by histological type of ovarian cancer, the highest prevalence of BRCA1 and BRCA2 pathogenic variants is around 22% in those with high-grade serous cancers. One study reported a prevalence of around 18% for pathogenic variants of BRCA1, BRCA2, RAD51C, RAD51D or BRIP1. There was also economic evidence that testing for pathogenic variants in people with ovarian cancer is cost effective. The committee agreed that this supports testing people with ovarian cancer to establish whether they carry a pathogenic variant. If a pathogenic variant is identified, it will help not only manage the person's ongoing care, but will also mean that family members can be tested for the pathogenic variant. Based on their expertise, the committee also recommended that people with other ovarian cancer histotypes associated with pathogenic variants should also be tested.

## How the recommendation might affect practice and services

According to current criteria, only people with non-mucinous epithelial ovarian cancer are referred for genetic testing. However, the committee also noted that testing of mucinous epithelial ovarian cancer is already common practice in many services. They further discussed that mucinous ovarian cancer is associated with Lynch syndrome, which is within the remit of this guideline and should therefore be included. However, in services where people with mucinous epithelial ovarian cancer are not currently being tested, it would represent a small change in practice due to the small number of people with mucinous ovarian cancer. There may also be more people diagnosed with rarer non-epithelial ovarian cancers accessing genetic counselling and genetic testing. However, these cancers are very rare and this recommendation is not expected to result in additional pressure on services.

[Return to recommendation](#)

## Gene panel testing

[Recommendations 1.5.1 and 1.5.2](#)

## Why the committee made the recommendations

Overall, the evidence showed that genes associated with an increased risk in ovarian

cancer were consistent with the genes recommended by the UK national genomic test directory. Therefore, the committee agreed that BRCA1, BRCA2, MLH1, MSH2, MSH6, RAD51C, RAD51D, BRIP1 and PALB2 should be the genes tested for in panel testing. They noted that the national genomic test directory has different gene panels for different conditions that may increase the risk of ovarian cancer, such as Lynch syndrome, or a family history of breast as well as ovarian cancer. Because such panels would contain different pathogenic variants to test for, the committee recommended which gene panel to use in relation to each person's family or personal history.

## How the recommendations might affect practice and services

The committee noted that it is already standard practice to use the gene panels recommended by the UK national genomic test directory. However, the committee noted that the criteria for a gene test are quite different to those in this guideline and that this would lead to more people becoming eligible for gene testing. The committee agreed that although this would have a cost impact, it would improve outcomes because more people would be identified as having a pathogenic variant, and risk-reducing strategies as well as cascade testing can be planned.

[Return to recommendations](#)

## Assessing the risk of developing ovarian cancer

[Recommendations 1.6.1 to 1.6.5](#)

### Why the committee made the recommendations

There was only evidence identified for 1 tool to assess the absolute risk of ovarian cancer (CanRisk), so the committee used this evidence as well as their experience and knowledge. They noted that the methods for assessing both probability of having a pathogenic variant and the risk of developing ovarian cancer are related, and stressed the need to take into account the recommendations in the section on assessing the risk of having a pathogenic variant (because someone with a high risk of having a pathogenic variant would therefore also have a higher likelihood of developing ovarian cancer).

The committee discussed the different services that may be involved in assessing someone's risk of developing ovarian cancer. Once an increased risk is established (as

outlined in the section on criteria for genetic testing) and the person is under the care of genetics services or a familial ovarian cancer multidisciplinary team, the service or team should offer to assess their risk of developing ovarian cancer. If it has already been established that the person has a pathogenic variant, the familial ovarian cancer multidisciplinary team would be responsible for the assessment.

The committee agreed that the evidence showed a reasonable level of accuracy for the CanRisk tool. It was also the only tool identified and they acknowledged that it would provide some framework for an assessment, so decided to give this as an example of a tool to use. They acknowledged that CanRisk is used to assess the risk of developing breast and ovarian cancer, and that more specific tools to assess the risk of developing ovarian cancer may be developed.

To use tools such as CanRisk, it is important to have as much information as possible. However, with limited information, the person should be asked whether they know of any other potential risk factors that may increase their risk of ovarian cancer. Based on their experience, the committee discussed the factors that may not be accurately assessed by tools, so highlighted some of these for clinicians to take into account when assessing risk.

The committee agreed that communicating risk and numerical data can be a challenge, particularly in light of uncertainties around estimates. They also thought it would be helpful to present this information in a variety of ways to make it more understandable. The committee referred to the NICE guideline on shared decision making. They also referred to the NICE guideline on familial breast cancer for risk factors that increase both breast and ovarian cancer.

The committee also made a [recommendation for research about tools or models to assess the absolute risk of developing ovarian cancer](#), to encourage further tools to be developed.

## **How the recommendations might affect practice and services**

It is standard practice to assess a person's risk of developing ovarian cancer. However, the way this is done varies, so the recommendations will improve efficiency and reduce variation.

[Return to recommendations](#)

# Primary preventive medicines

Recommendations 1.7.1 to 1.7.4

## Why the committee made the recommendations

### Aspirin

The evidence on aspirin did not show a protective effect in terms of ovarian cancer incidence, so the committee did not recommend it for the sole purpose of reducing ovarian cancer risk. However, they noted that there is existing NICE guidance on the use of aspirin to reduce the risk of colorectal cancer in people with Lynch syndrome. Because people with Lynch syndrome are included in the scope of this guideline, the committee felt it was important to link to the NICE guideline on colorectal cancer to ensure that they are aware of this recommendation.

### Combined oral contraceptives

The committee agreed, based on their knowledge and experience, that combined oral contraceptives can be associated with a lower risk of ovarian cancer, but long-term use is associated with an increase in breast cancer. They therefore decided to only recommend oral contraceptives as a preventive medicine in particular circumstances: when the reduction in ovarian cancer risk (based on for example age, family history) may outweigh an increased breast cancer risk; and after taking into account whether the timing of risk-reducing surgery is appropriate or not (for example, it may not be appropriate because of age and planned pregnancy).

In the committee's experience, people are not always fully informed about the potential risks (increased risk of developing breast cancer) and benefits (reduced risk of developing ovarian cancer) of combined oral contraceptives, which is necessary for informed decision making. They therefore recommended that this should be discussed so that people can make an informed choice.

Given that evidence was only identified for 2 types of medicines, the committee decided to make a recommendation for research about the effectiveness of primary preventive medicines for reducing the incidence of ovarian cancer.



## How the recommendations might affect practice

The recommendations will not significantly change practice.

[Return to recommendations](#)

## Risk-reducing surgery

### Factors to take into account when considering risk-reducing surgery

[Recommendations 1.8.1 to 1.8.5](#)

#### Why the committee made the recommendations

The committee discussed general factors that need to be taken into account or discussed with the person when considering risk-reducing surgery. Risk-reducing surgery means that the person would become unable to become pregnant because their ovaries and fallopian tubes would be removed. The committee agreed that risk-reducing surgery should not be offered to people planning to conceive naturally because the incidence of ovarian cancer in people younger than 35 is relatively small. Based on the evidence, they also specified the criteria for offering risk-reducing surgery. The criteria relate to people who have a total lifetime risk of ovarian cancer of 5% or over because they have either a pathogenic variant or a strong family history. The committee noted that it is important to attempt to verify the family history if possible (by exploring testing with the person or their family, or via the Cancer Registry or other medical documents).

The committee discussed the importance of supporting people to make informed decisions, and agreed the information and support that people should receive.

The committee agreed that decisions around risk-reducing surgery can cause anxiety and stress. They discussed that the psychological impact of surgery should be taken into account in discussions with the person, and that psychological support before surgery may be needed.

The committee also discussed information and support to aid decision making, particularly around menopause and managing symptoms for premenopausal people considering

bilateral salpingo-oophorectomy.

The committee noted, based on their knowledge and experience, that decisions about risk-reducing surgery for people who are carriers of bi-allelic pathogenic variants in mismatch repair genes (for example, homozygous PMS2) are complex. However, they are also very rare so the committee agreed that a referral to a specialist multidisciplinary team would be needed for discussions about potential risk-reducing surgery.

## How the recommendations might affect practice

The recommendations will reinforce common good practice and will lead to safer practice and better outcomes.

[Return to recommendations](#)

## Types of risk-reducing surgery and timing in relation to the person's specific pathogenic variant

[Recommendations 1.8.6 to 1.8.11 and table 5](#)

### Why the committee made the recommendations

The committee agreed that decisions related to risk-reducing surgery for ovarian cancer should take into account the NICE guideline on familial breast cancer because some of the genes associated with ovarian cancer would also increase the risk of breast cancer, so considerations around risk-reducing mastectomy should be made in line with the NICE familial breast cancer guideline.

The committee discussed the evidence that bilateral salpingo-oophorectomy improves overall survival. They noted that most of the evidence came from studies with carriers of the BRCA1 or BRCA2 variants. Based on the evidence, they recommended bilateral salpingo-oophorectomy for people at increased risk of ovarian cancer with BRCA1 and BRCA2, and also RAD51C, RAD51D, BRIP1 or PALB2, which are also associated with an increased risk of ovarian cancer.

The MLH1, MSH2 or MSH6 pathogenic variants are associated with Lynch syndrome, which is associated with an increased risk of endometrial as well as ovarian cancer. Although there was no evidence identified related to different types of surgery within this

specific group, the committee decided that total hysterectomy as well as bilateral salpingo-oophorectomy should be recommended to prevent both of these types of cancers. They noted that PMS2 is also associated with Lynch syndrome (and is therefore on the associated gene panel). PMS2 increases the risk of endometrial cancer alone rather than endometrial as well as ovarian cancer. They therefore did not add it to the table of risk-reducing surgery for people at risk of ovarian cancer.

The committee made separate recommendations related to the PMS2 pathogenic variant because of its link to Lynch syndrome. People with this pathogenic variant have an increased risk of endometrial cancer alone, but could have an increased risk of ovarian cancer if there is also a family history of ovarian cancer. They therefore considered it to be safe to only recommend total hysterectomy for people with a heterogenous PMS2 pathogenic variant unless there is also a family history of ovarian cancer when additional bilateral salpingo-oophorectomy could be considered.

The committee used their knowledge and experience to agree the minimum ages for risk-reducing surgery, and discussed that there could be exceptional circumstances when risk-reducing surgery could be considered earlier, based on an individualised assessment.

The committee acknowledged that an argument could be made for having salpingectomy first and then delayed oophorectomy, which would avoid a surgical menopause. They noted that some of the evidence related to this showed promise. However, the evidence had very short follow-up and therefore, the important outcomes such as overall survival and ovarian cancer incidence could not be measured.

The committee noted that MLH1, MSH2, MSH6 and PMS2 increase the risk of endometrial cancer, and therefore a hysterectomy is indicated only for carriers of these pathogenic variants. The committee recommended against hysterectomy for carriers of other pathogenic variants unless there would be other reasons for this to be done.

## **How the recommendations might affect practice**

Risk-reducing surgery is already current practice, but the timing of when it is offered varies. There is currently no specific consideration for the timing related to specific pathogenic variants other than BRCA1 and BRCA2, and the committee noted that the recommendations will standardise this. The recommended ages for risk-reducing surgery correspond with increasing cancer incidence and offer the greatest potential for cancer reduction and associated healthcare cost savings.

The committee noted that broader eligibility criteria for genetic testing will lead to more people opting for risk-reducing surgery. This could put additional pressure on existing services. However, risk-reducing surgeries are generally less complex and require less extensive preoperative and postoperative care compared with ovarian cancer surgery. It would also save costs associated with other cancer treatment as well as save lives. Therefore, in the long term, risk-reducing surgery is likely to result in better outcomes for people and cost savings for services.

[Return to recommendations](#)

## **Tests before risk-reducing surgery, referral to the gynaecology oncology multidisciplinary team, and what to consider during surgery**

[Recommendations 1.8.12 to 1.8.17](#)

### **Why the committee made the recommendations**

#### **Tests before risk-reducing surgery**

The committee used their knowledge and experience to agree the tests that should be carried out before risk-reducing surgery to minimise the risk of missing asymptomatic ovarian or endometrial cancer.

#### **Referral to the gynaecology oncology multidisciplinary team**

There was evidence that risk-reducing surgery is effective and will identify asymptomatic cancer in some people undergoing risk-reducing surgery. Based on this evidence, the committee recommended that if this is identified before or after surgery, a referral should be made to the gynaecology oncology multidisciplinary team so that cancer treatment can be planned.

#### **During risk-reducing surgery**

Based on their knowledge and experience, the committee agreed that minimal access surgery is generally preferred over a laparotomy. They noted that some of the evidence included peritoneal washing, but the study included this in both arms of the comparison. It

was therefore unclear whether this would be more effective than not using it. However, the committee recommended that peritoneal washings should be taken to prevent missing cancerous cells that may have spread to the peritoneal cavity. Missing cancerous cells, such as serous tubal intraepithelial carcinoma (STIC), would affect staging and ongoing management. In their experience, the committee were aware that up to 5% of incidental cancers could be missed if ultrasound alone is used, and that ultrasound is particularly unreliable in Lynch syndrome. They therefore recommended that any lesions noticed during surgery should be investigated – even if they are found outside the organs that are being removed (such as in the peritoneal cavity) – to increase the likelihood of finding any asymptomatic cancers.

### **How the recommendations might affect practice**

The recommendations generally reflect current practice and will reduce variation. Taking peritoneal washings is not currently practised everywhere but identifying cancer early, correct staging and the appropriate treatment will lead to better outcomes.

[Return to recommendations](#)

## **Ovarian cancer surveillance by the familial ovarian cancer multidisciplinary team for people who choose to delay or not have risk-reducing surgery**

[Recommendations 1.8.18 to 1.8.20](#)

### **Why the committee made the recommendations**

The recommendations are based on limited evidence of the effectiveness of ovarian cancer surveillance as well as how accurately the methods diagnose cancer. Not many studies were identified, and the available studies were limited in the applicability of the populations and the comparisons investigated.

The committee agreed that risk-reducing surgery is always superior to surveillance in relation to preventing cancer and therefore decided not to recommend surveillance because it could encourage people to delay or avoid risk-reducing surgery; the evidence supported this. The committee also discussed the evidence that surveillance is associated with an earlier detection of cancer but also noted a lack of data on an associated survival benefit. However, the committee acknowledged that because people often have children

later in life, they may delay or choose to not have risk-reducing surgery. The committee discussed, based on their expertise and the evidence, that the risk of ovarian cancer rises with age and incidence curves vary according to the pathogenic variant, and therefore suggested varying ages for onset of surveillance if surgery was delayed or declined.

They were also concerned about the risk of false-positive surveillance results so recommended the test with the best performance characteristics in relation to false-positive and false-negative rates. If surveillance is carried out, the evidence showed that serial 4-monthly CA125 longitudinal testing using an algorithm was the most accurate test for this. In the evidence, this was based on the Risk of Ovarian Cancer Algorithm (ROCA) Test, but the committee did not want to rule out using other CA125 longitudinal testing using another algorithm as long as it has demonstrated accuracy. The committee acknowledged that an infrastructure needs to be in place, so recommended that all surveillance activities should come under the remit of the familial ovarian cancer multidisciplinary team who should coordinate, audit and interpret it, using a call and recall mechanism. They recommended that there should be a review at least once a year to discuss the recommendation of having risk-reducing surgery.

The committee agreed that people should be made aware that surveillance is not an alternative to risk-reducing surgery and that risk-reducing surgery is the only way to reduce their risk of developing ovarian cancer. It should also be explained that surveillance would involve 4-monthly blood tests with an algorithm to analyse results and that there is a possibility that a test result could be false. The committee decided that this information is needed to encourage people not to delay the recommended risk-reducing surgery indefinitely.

The committee also made a recommendation for research to obtain more evidence on the long-term benefits and risks of ovarian cancer surveillance.

## **How the recommendations might affect practice**

Because surveillance would be a change to current practice, the infrastructure for services is not established. Implementing the recommendations may be a challenge and associated with a considerable resource impact. Implementation would take up clinical as well as administrative time, for example, screening invitations, appointments, cost of tests (the ROCA Test is currently not available on the NHS), interpretation of tests and providing the outcomes of tests. Surveillance has been shown to detect ovarian cancer at an earlier stage but it has not been shown to translate into a survival benefit. The committee also

noted that most people would be expected to opt for risk-reducing surgery; hence, only very few people would require surveillance, potentially mitigating some of the resource impact.

[Return to recommendations](#)

## Pathology protocol for handling specimens from risk-reducing surgery

[Recommendations 1.9.1 to 1.9.5](#)

### Why the committee made the recommendations

The committee agreed, based on their knowledge and experience, that people undergoing risk-reducing surgery are at increased risk of having an occult precancerous or malignant lesion, so intensive pathological investigation is needed. The committee discussed that pathology protocols for the detection of microscopic lesions found within the fallopian tubes have changed over time. The SEE-FIM (Sectioning and Extensively Examining the FIMbriated End) protocol entails multiple sagittal sections of fimbriae combined with 2 mm-thick sections of the remainder. The committee agreed, based on their knowledge and experience, that this type of sectioning is necessary to maximise the detection of precancerous lesions and early cancers.

The committee discussed that immunohistochemistry is a relatively inexpensive, yet informative, investigation that is available in all NHS pathology laboratories. Immunohistochemistry (for p53 and Ki67/MIB1) helps in the identification of serous tubal intraepithelial carcinoma (STIC) and high-grade serous ovarian carcinomas. The committee agreed that investigations of these markers are only necessary if a premalignant or malignant lesion is suspected on morphological examination. They should not be performed in morphologically normal fallopian tubes because immunohistochemistry would not provide any additional information.

The committee agreed that to enable accurate reporting, surgical specimens need to be correctly labelled. It is not possible to determine the laterality of an adnexa once it has been removed from the body. Therefore, at the time of removal, surgeons should ensure adnexal specimens are submitted in 2 separate containers and labelled as originating from either the left or right adnexa. This will enable pathologists to issue accurate reports.

The committee also agreed that peritoneal cytology is needed to correctly stage any precancerous or cancerous lesions and detect occult peritoneal cancers.

The committee noted that people with Lynch syndrome are at increased risk of developing endometrial cancers. In Lynch syndrome, there is a propensity for endometrial cancers to arise within the lower uterine segment. The committee decided that the entire endometrium, including the lower uterine segment, should be submitted for pathological examination to ensure that such cancers and precancerous lesions are identified.

## How the recommendations might affect practice

There is already widespread use of the SEE-FIM protocol by pathologists in dealing with risk-reducing surgery specimens. Where this is not currently used, it will improve detection of occult precancers and cancers and therefore may lead to earlier treatment. Therefore, the recommendations will standardise the use of this pathology protocol.

[Return to recommendations](#)

## Hormone replacement therapy after risk-reducing surgery

[Recommendations 1.10.1 to 1.10.4](#)

### Why the committee made the recommendations

There was little evidence about hormone replacement therapy (HRT) after risk-reducing salpingo-oophorectomy. Studies were small and most had follow-up that was too short for some of the outcomes investigated, such as cardiovascular events for which the baseline risk is relatively low at a younger age. The committee noted that the evidence showed that HRT is effective in decreasing vasomotor symptoms and agreed that this is in line with the general literature on managing troublesome vasomotor symptoms. There was evidence that HRT is associated with fewer diagnoses of osteoporosis as well as higher bone mineral density. Despite the relatively small evidence base, this was consistent with the committee's experience and knowledge. They recommended that HRT should be offered to prevent loss of bone density and manage symptoms and, based on their knowledge and experience, decided that it should be offered until the average age of menopause (which is usually around 51 years).



The committee agreed that premenopausal women and people with female reproductive organs without a history of breast cancer should be offered HRT after risk-reducing surgery. They agreed that those with a history of certain types of breast cancer may sometimes be prescribed HRT after risk-reducing bilateral salpingo-oophorectomy, but that this should only be offered after advice from their breast cancer team. This is to ensure that HRT would not increase the risk of breast cancer recurrence given other potential risk factors (for example, oestrogen receptor-positive breast cancer).

The committee noted that oestrogen-only HRT is appropriate after a hysterectomy, whereas only combined preparations are appropriate for those with a uterus. The committee were also aware of a [Royal College of Obstetricians and Gynaecologists \(RCOG\) Scientific impact paper on HRT after risk-reducing salpingo-oophorectomy](#). To be consistent with this paper, they agreed that in most cases, HRT could be started immediately after surgery unless this is not clinically appropriate. They also decided, in line with the RCOG recommendations, that it may be advisable to insert a levonorgestrel intrauterine system at the same time as the surgery, if this was the preferred HRT option. The committee discussed whether or not HRT should be continued after the person reaches the average age of menopause. They agreed that although this is a possibility, it should not automatically happen. If a person wants to take HRT beyond the average age of menopause, there should first be a discussion to assess the person's individual risks and benefits.

The committee were aware that genitourinary symptoms are effectively treated by vaginal oestrogen for people who have not had breast cancer. This is consistent with the conclusions from the [NICE guideline on menopause](#).

Because of the sparsity of evidence, the committee made a [recommendation for research on the effectiveness and safety of HRT after risk-reducing surgery](#).

## How the recommendations might affect practice

The committee noted that these recommendations align with other NICE guidance and therefore should not change current practice.

[Return to recommendations](#)

## Context

Familial ovarian cancer affects people born with female reproductive organs (ovaries, fallopian tubes and/or a uterus). Although in this guideline, the term ovarian cancer is used throughout, there is now evidence that most high-grade serous cancers (the most common type of ovarian cancer) arise from the distal fallopian tube from a precursor lesion referred to as serous tubal intraepithelial carcinoma (STIC).

In the UK, between 340,000 and 440,000 women have a pathogenic variant associated with an increased risk of ovarian cancer. This includes pathogenic variants in BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2, MLH1, MSH2 and MSH6 genes. It is estimated that 15% to 20% of those with high-grade epithelial ovarian cancer also carry a pathogenic variant associated with increased risk of ovarian cancer.

Most of the people who carry a pathogenic variant for ovarian cancer do not have a family history suggestive of a genetic risk. This means many people have not sought testing for high-risk ovarian cancer pathogenic variants. Current best estimates are that only 3% of people with a pathogenic variant know that they are carriers. This proportion will increase with improved availability of genetic testing.

Most women and people born with female reproductive organs who carry a pathogenic variant will not develop ovarian cancer. This guideline recommends how to assess the risk of having a pathogenic variant and the risk of developing ovarian cancer, what risk-reducing interventions should or should not be offered, and what information and support should be given.

The guideline does not cover risk management and decision-making support for people born with male reproductive organs who have, or are at risk of having, a pathogenic variant associated with ovarian cancer. This is because they are not at risk of developing ovarian cancer, and the decisions that they would have to make are different and outside the scope of this guideline.

## Finding more information and committee details

To find NICE guidance on related topics, including guidance in development, see the [NICE topic page on ovarian cancer](#).

For full details of the evidence and the guideline committee's discussions, see the [evidence reviews](#). You can also find information about [how the guideline was developed](#), including [details of the committee](#).

NICE has produced [tools and resources](#) to help you put this guideline into practice. For general help and advice on putting our guidelines into practice, see [resources to help you put NICE guidance into practice](#).

ISBN: 978-1-4731-5815-3

## Accreditation

